JP2024519397A - ２つのｔｒａｉｌ三量体を含むスーパーｔｒａｉｌ分子 - Google Patents

２つのｔｒａｉｌ三量体を含むスーパーｔｒａｉｌ分子 Download PDF

Info

Publication number
JP2024519397A
JP2024519397A JP2023573077A JP2023573077A JP2024519397A JP 2024519397 A JP2024519397 A JP 2024519397A JP 2023573077 A JP2023573077 A JP 2023573077A JP 2023573077 A JP2023573077 A JP 2023573077A JP 2024519397 A JP2024519397 A JP 2024519397A
Authority
JP
Japan
Prior art keywords
trail
fusion polypeptide
cancer
fusion
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519397A5 (enExample
Inventor
チャン シングオ
ホン ウェイ
Original Assignee
ベイジン アンシンフエイド バイオテック． シーオー．， エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジン アンシンフエイド バイオテック． シーオー．， エルティーディー filed Critical ベイジン アンシンフエイド バイオテック． シーオー．， エルティーディー
Publication of JP2024519397A publication Critical patent/JP2024519397A/ja
Publication of JP2024519397A5 publication Critical patent/JP2024519397A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Lubricants (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023573077A 2021-05-27 2022-05-27 ２つのｔｒａｉｌ三量体を含むスーパーｔｒａｉｌ分子 Pending JP2024519397A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/096498 2021-05-27
CN2021096498 2021-05-27
PCT/CN2022/095472 WO2022247923A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Publications (2)

Publication Number Publication Date
JP2024519397A true JP2024519397A (ja) 2024-05-10
JP2024519397A5 JP2024519397A5 (enExample) 2025-06-03

Family

ID=84228436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573077A Pending JP2024519397A (ja) 2021-05-27 2022-05-27 ２つのｔｒａｉｌ三量体を含むスーパーｔｒａｉｌ分子

Country Status (9)

Country Link
US (1) US20240254193A1 (enExample)
EP (1) EP4347665A4 (enExample)
JP (1) JP2024519397A (enExample)
KR (1) KR20240013766A (enExample)
CN (1) CN117396520A (enExample)
AU (1) AU2022280269A1 (enExample)
CA (1) CA3220239A1 (enExample)
IL (1) IL308618A (enExample)
WO (1) WO2022247923A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120475984A (zh) * 2023-01-05 2025-08-12 国家纳米科学中心 Dna-trail复合物及其治疗肿瘤的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518949A (ja) * 1999-12-30 2003-06-17 アポクシ・ソシエテ・アノニム 組み換え融合タンパク質のダイマー、トリマー、クアトロマー又はペンタマーのバイマー又はオリゴマー
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof
EP3145530A1 (en) * 2014-04-21 2017-03-29 Theraly Pharmaceuticals Inc. Trail receptor agonists for treatment of fibrotic diseases
WO2018183671A1 (en) * 2017-03-29 2018-10-04 Tdw Group Protein conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
WO2017194442A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518949A (ja) * 1999-12-30 2003-06-17 アポクシ・ソシエテ・アノニム 組み換え融合タンパク質のダイマー、トリマー、クアトロマー又はペンタマーのバイマー又はオリゴマー
EP3145530A1 (en) * 2014-04-21 2017-03-29 Theraly Pharmaceuticals Inc. Trail receptor agonists for treatment of fibrotic diseases
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof
WO2018183671A1 (en) * 2017-03-29 2018-10-04 Tdw Group Protein conjugates

Also Published As

Publication number Publication date
US20240254193A1 (en) 2024-08-01
AU2022280269A1 (en) 2023-11-30
CN117396520A (zh) 2024-01-12
WO2022247923A1 (en) 2022-12-01
CA3220239A1 (en) 2022-12-01
EP4347665A4 (en) 2025-07-30
EP4347665A1 (en) 2024-04-10
KR20240013766A (ko) 2024-01-30
IL308618A (en) 2024-01-01
AU2022280269A9 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
ES2278663T3 (es) Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf.
EP1506787B1 (en) Vascular endothelial cell growth factor antagonists
US10206980B2 (en) IL-15 heterodimeric protein and uses thereof
JP5564268B2 (ja) 成長因子と結合する融合タンパク質
JP6523331B2 (ja) 単鎖ｔｒａｉｌ受容体アゴニストタンパク質
US20180346549A1 (en) Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines and Their Use
CA2978526A1 (en) Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases
WO2021081193A1 (en) Methods of administration of if-2 receptor agonists
US20230331858A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
US20240101630A1 (en) Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
CA2723823C (en) Conjugates for the treatment of mesothelioma
JP7221545B2 (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
JP2024519397A (ja) ２つのｔｒａｉｌ三量体を含むスーパーｔｒａｉｌ分子
JP2007524671A (ja) Ｍ−ｃｓｆムテインおよびその使用
US12168686B2 (en) Method of treating cancer using disulfide-linked trimeric OX40L
US20210401927A1 (en) Peptides Having Immunomodulatory Properties
US20220143130A1 (en) Peptides Having Immunomodulatory Properties
HK40101761A (zh) 包含两个trail三聚体的超trail分子
WO2012019192A2 (en) Cell-permeable molecules as growth factor receptor antagonists
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
US20150118228A1 (en) Broad spectrum erbb ligand binding molecules and methods for their use
WO2026003203A1 (en) Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2024050058A2 (en) Ul141 variants, compositions thereof and methods of using the same for cancer immunotherapy
WO2026056809A1 (zh) 小肽及其在制备治疗癌症药物中的应用
HK1210725A1 (en) Osteoprotegerin derived composition and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317